Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

MLA

Priti S. Hegde, et al. “Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 8, Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3ba06ab37aff1043081129c54606443a&authtype=sso&custid=ns315887.

APA

Priti S. Hegde, Michael S. Gordon, Mario Sznol, David F. McDermott, Marcella Fassò, Wei Zou, Yan V. Wang, Jeffrey R. Infante, Thomas Powles, John D. Powderly, Gregg Fine, Omid Hamid, Jeffrey A. Sosman, & Christophe Massard. (2016). Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(8).

Chicago

Priti S. Hegde, Michael S. Gordon, Mario Sznol, David F. McDermott, Marcella Fassò, Wei Zou, Yan V. Wang, et al. 2016. “Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3ba06ab37aff1043081129c54606443a&authtype=sso&custid=ns315887.